P
Porton Pharma Solutions Ltd
SZSE:300363
Porton Pharma Solutions Ltd
SZSE:300363
Price:
20.34
CNY
-3.19%
Market Cap:
¥11.1B
Relative Value
The Relative Value of one Porton Pharma Solutions Ltd stock under the Base Case scenario is 15.69 CNY. Compared to the current market price of 20.34 CNY, Porton Pharma Solutions Ltd is Overvalued by 23%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
15.69
CNY
Overvaluation 23%
P
Multiples Across Competitors
Competitors Multiples
Porton Pharma Solutions Ltd Competitors
Porton Pharma Solutions Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
P
|
Porton Pharma Solutions Ltd
SZSE:300363
|
11.1B CNY | 3.2 | -7 878.1 | 187.9 | 187.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
866.9B USD | 13.3 | 42 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.1B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
250.6B CHF | 4.1 | 19.5 | 11.5 | 13 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.9B GBP | 5 | 28.6 | 15.9 | 22.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.9B CHF | 5.2 | 20.8 | 12.9 | 16.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.9B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117B USD | 2.4 | 16.6 | 7 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
